Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for treatment of metabolic and endocrine disorders. The Company's clinical programs include VK2809, an orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is being evaluated in a Phase II b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. The Company is developing VK0214, which is also an orally available, tissue and receptor-subtype selective agonist of TRb for X-linked adrenoleukodystrophy (X-ALD), a rare X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. It is also developing VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the treatment of various metabolic disorders.

Employees

Sector

Biotechnology & Medical Research

Calendar

Jul. 22 - Q2 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
25-06-20	26.04 $	-0.92%	650,333
25-06-18	26.28 $	-0.57%	2,281,780
25-06-17	26.43 $	-1.97%	2,266,759
25-06-16	26.96 $	+3.37%	2,995,163
25-06-13	26.08 $	-8.75%	6,095,496

Delayed Quote Nasdaq, June 18, 2025 at 04:00 pm EDT

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

26.28USD

Average target price

90.26USD

Spread / Average Target

+243.47%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Real-time Estimate Cboe BZX Other stock markets 10:42:04 2025-06-20 am EDT			5-day change	1st Jan Change
25.70 ^USD	-2.21%		-0.19%	-35.31%

Jun. 05	Viking Therapeutics, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-05-2025 11:40 AM
May. 16	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE

Capitalization	2.95B 2.57B 2.42B 2.2B 4.05B 256B 4.57B 28.52B 11.01B 117B 11.08B 10.84B 430B	P/E ratio 2025 *	-13.6x	P/E ratio 2026 *	-10x
Enterprise value	2.21B 1.93B 1.81B 1.64B 3.03B 192B 3.42B 21.34B 8.24B 87.37B 8.29B 8.11B 322B	EV / Sales 2025 *	1,501x	EV / Sales 2026 *	365x
Free-Float	92.4%	Yield 2025 *	-	Yield 2026 *	-

Viking Therapeutics, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-05-2025 11:40 AM	Jun. 05
Weight-loss drug developers line up to tap lucrative market as competition heats up	May. 16	RE
Cantor Fitzgerald Initiates Viking Therapeutics at Overweight With $104 Price Target	Apr. 29	MT
Truist Securities Cuts Viking Therapeutics Price Target to $75 From $95, Maintains Buy Rating	Apr. 25	MT
B. Riley Adjusts Price Target on Viking Therapeutics to $85 From $96, Maintains Buy Rating	Apr. 24	MT
Viking Therapeutics Q1 Loss Widens; Shares Drop After Hours	Apr. 23	MT
Earnings Flash (VKTX) Viking Therapeutics Q1 Loss of $0.41 vs. FactSet Est Loss $0.33	Apr. 23	MT
Viking Therapeutics, Inc., Q1 2025 Earnings Call, Apr 23, 2025	Apr. 23
Viking Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	Apr. 23	CI
Oppenheimer Cuts Price Target on Viking Therapeutics to $100 From $164, Keeps Outperform Rating	Apr. 23	MT
Lilly weight-loss pill works as well as Ozempic, shares surge	Apr. 17	RE
Wall Street rises as investors weigh tariff exemptions	Apr. 14	RE
Tech stocks power Wall St higher after Trump's tariff relief for some electronics	Apr. 14	RE

Cantor Fitzgerald Initiates Viking Therapeutics at Overweight With $104 Price Target	Apr. 29	MT
Truist Securities Cuts Viking Therapeutics Price Target to $75 From $95, Maintains Buy Rating	Apr. 25	MT
B. Riley Adjusts Price Target on Viking Therapeutics to $85 From $96, Maintains Buy Rating	Apr. 24	MT
Oppenheimer Cuts Price Target on Viking Therapeutics to $100 From $164, Keeps Outperform Rating	Apr. 23	MT
Goldman Sachs Initiates Viking Therapeutics With Neutral Rating, $30 Price Target	Apr. 08	MT

Viking Therapeutics, Inc. Stock

Equities

VKTX

US92686J1060

Biotechnology & Medical Research

Valuation: Viking Therapeutics, Inc.

Chart: Viking Therapeutics, Inc.

Latest news: Viking Therapeutics, Inc.

Last Transcript: Viking Therapeutics, Inc.

Analysts' recommendations: Viking Therapeutics, Inc.

Press Releases: Viking Therapeutics, Inc.

News in other languages: Viking Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Viking Therapeutics, Inc.

ETFs: Viking Therapeutics, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

Viking Therapeutics : June 2025 Corporate Presentation	Jun. 13	PU
Viking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025	Apr. 16	PR
Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity	Mar. 26	PR
Viking Therapeutics Signs Broad Manufacturing Agreement With CordenPharma to Support Commercialization of VK2735	Mar. 11	PR
Viking Therapeutics to Participate at Upcoming Investor Conferences	Mar. 04	PR

Píldora adelgazante de Eli Lilly funciona tan bien como Ozempic en un ensayo	Apr. 17
MÄRKTE USA/Fester - Hoffnung auf weitere Zollausnahmen stützt Kurse	Apr. 14
Pfizer met fin au développement de sa pilule amaigrissante danuglipron	Apr. 14
AKTIEN IM FOKUS 3: Kursrutsch bei Novo Nordisk und Gerresheimer - Lilly steigt	Dec. 20
AKTIEN IM FOKUS 2: Studie wirft Novo Nordisk weit zurück - Gerresheimer schwach	Dec. 20

1 day	-0.57%
1 week	-8.05%
Current month	-1.94%
1 month	-4.44%
3 months	-12.60%
6 months	-36.66%
Current year	-34.69%

1 week	25.8	27.13
1 month	25.61	30.17
Current year	18.92	43.55
1 year	18.92	81.73
3 years	2.32	99.41
5 years	2.02	99.41
10 years	0.88	99.41

Manager	Title	Age	Since
Brian Lian CEO	Chief Executive Officer	59	2012-09-23
Gregory Zante DFI	Director of Finance/CFO	54	2021-01-03
Marianne Mancini COO	Chief Operating Officer	60	2021-01-03

Director	Title	Age	Since
Lawson Macartney CHM	Chairman	67	2015-04-30
Brian Lian CHM	Chairman	59	2012-09-23
Matthew Foehr BRD	Director/Board Member	52	2014-04-30

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
VIKING THERAPEUTICS, INC.	-0.57%	-8.05%	-48.10%	+1,068.00%	2.95B
REGENERON PHARMACEUTICALS, INC.	+0.89%	-1.62%	-50.59%	-11.63%	54.27B
ARGENX SE	+0.40%	-5.47%	+32.45%	+45.83%	33.13B
WUXI APPTEC CO., LTD.	-1.17%	-4.11%	+54.82%	-32.36%	25.88B
BIONTECH SE	-0.43%	-0.38%	+21.15%	-16.48%	25.71B
INSMED INCORPORATED	-0.82%	+2.66%	+51.66%	+435.31%	18.89B
SUMMIT THERAPEUTICS INC.	+1.46%	-0.10%	+153.65%	+1,954.89%	14.97B
GENMAB A/S	+0.09%	-5.10%	-21.79%	-30.56%	13.28B
WUXI BIOLOGICS (CAYMAN) INC.	-0.21%	-14.11%	+105.20%	-64.48%	12.49B
EXELIXIS, INC.	-1.45%	-2.45%	+89.03%	+119.59%	11.11B
Average	-0.18%	-3.83%	+38.75%	+346.81%	21.27B
Weighted average by Cap.	+0.04%	-2.96%	+25.58%	+189.90%

	2025 *	2026 *
Net sales	1.47M 1.28M 1.2M 1.1M 2.02M 128M 2.28M 14.21M 5.49M 58.19M 5.52M 5.4M 214M	6.45M 5.62M 5.28M 4.8M 8.86M 560M 9.99M 62.32M 24.06M 255M 24.2M 23.68M 940M
Net income	-219M -191M -179M -163M -300M -18.99B -339M -2.11B -816M -8.65B -820M -803M -31.86B	-302M -263M -247M -225M -415M -26.23B -468M -2.92B -1.13B -11.95B -1.13B -1.11B -44.02B
Net Debt	-744M -648M -609M -554M -1.02B -64.58B -1.15B -7.19B -2.77B -29.42B -2.79B -2.73B -108B	-601M -524M -492M -447M -825M -52.17B -931M -5.81B -2.24B -23.77B -2.25B -2.21B -87.55B